02211.HK
Universal Health International Group Holding Limited
HKSE · Healthcare · Medical - Pharmaceuticals · CN
HKD 0.68
+6.25%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.5B | 711.5M | 1.1B | 1.3B | 1.3B |
| Cost of Revenue | 1.2B | 605.0M | 909.2M | 1.2B | 1.3B |
| Gross Profit | 244.5M | 106.5M | 179.9M | 222.6M | 215.3M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 272.9M | 136.3M | 205.6M | 303.1M | 380.4M |
| General & Admin Expense | 67.9M | 33.9M | 40.6M | 57.9M | 58.0M |
| Selling & Marketing Expense | 175.0M | 102.5M | 165.0M | 245.2M | 322.3M |
| Other Expenses | (20.5M) | (4.3M) | (25.8M) | 9.2M | 12.5M |
| Total Operating Expenses | 252.4M | 132.0M | 179.8M | 312.3M | 392.9M |
| Cost and Expenses | 1.5B | 737.0M | 1.1B | 1.4B | 1.5B |
| Operating Income (EBIT) | (7.9M) | (25.5M) | 82.0K | (98.4M) | (188.7M) |
| Non-Operating | |||||
| Interest Income | 881.8K | 622.9K | 383.0K | 925.0K | 2.1M |
| Interest Expense | (78.8K) | 1.2M | 1.4M | 1.3M | 1.2M |
| Net Interest Income | 774.7K | (1.1M) | (973.0K) | (345.0K) | 744.0K |
| Other Non-Op Income/Expense | (1.5M) | 2.6M | (2.9M) | (13.7M) | 697.0K |
| Non-Operating Income (excl Interest) | (11.1M) | — | 1.5M | (12.0M) | (19.0M) |
| EBT (Pre-Tax Income) | (8.4M) | (22.9M) | (2.8M) | (112.1M) | (188.0M) |
| Income Tax Expense | 1.9M | 2.7M | (3.4M) | (6.0M) | 1.5M |
| Bottom Line | |||||
| Net Income | (10.7M) | (26.0M) | 413.0K | (105.4M) | (187.6M) |
| Earnings from Cont. Ops | (6.4M) | (25.7M) | 580.0K | (106.1M) | (188.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (10.7M) | (26.0M) | 413.0K | (105.4M) | (187.6M) |
| Per Share | |||||
| Basic EPS | (HK$0.26) | (HK$0.32) | HK$0.00 | (HK$0.20) | (HK$0.52) |
| Diluted EPS | (HK$0.26) | (HK$0.32) | HK$0.00 | (HK$0.20) | (HK$0.52) |
| Revenue Per Share | HK$15.14 | HK$8.88 | HK$1.63 | HK$2.22 | HK$2.90 |
| Shares | |||||
| Basic Shares Outstanding | 97.5M | 80.1M | 668.6M | 583.1M | 439.8M |
| Diluted Shares Outstanding | 97.5M | 80.1M | 668.6M | 583.1M | 439.8M |
| Profitability Metrics | |||||
| EBITDA | 32.4M | (11.8M) | 12.6M | (70.6M) | (160.8M) |
| D&A | 29.2M | 13.7M | 14.0M | 15.8M | 26.1M |
| EBIT | 3.2M | (25.5M) | (1.4M) | (86.4M) | (186.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025